Nasal Polyposis - Pipeline Review, H2 2017

Global Markets Direct’s, ‘Nasal Polyposis - Pipeline Review, H2 2017’, provides an overview of the Nasal Polyposis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasal Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasal Polyposis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Nasal Polyposis

The report reviews pipeline therapeutics for Nasal Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Nasal Polyposis therapeutics and enlists all their major and minor projects

The report assesses Nasal Polyposis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Nasal Polyposis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nasal Polyposis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nasal Polyposis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

OptiNose US Inc

Regeneron Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

OptiNose US Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasal Polyposis - Overview

Nasal Polyposis - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasal Polyposis - Overview

Nasal Polyposis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nasal Polyposis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasal Polyposis - Companies Involved in Therapeutics Development

Cumberland Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

OptiNose US Inc

Regeneron Pharmaceuticals Inc

Nasal Polyposis - Drug Profiles

AK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ifetroban sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasal Polyposis - Dormant Projects

Nasal Polyposis - Product Development Milestones

Featured News & Press Releases

Feb 09, 2017: Michael F. Marino Joins OptiNose as Chief Legal Officer

Jan 31, 2017: OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375

Jan 26, 2017: OptiNose Appoints Keith Goldan as Chief Financial Officer

Sep 29, 2016: Tom Gibbs Joins OptiNose as Chief Commercial Officer

Sep 08, 2016: Allakos Initiates Phase 2 Trial of AK001 in Patients with Nasal Polyposis

Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab

Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association

Sep 24, 2015: OptiNose Announces Positive Results of Second Phase III Pivotal Trial for OPN-375

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Nasal Polyposis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development ...

List of Tables

Number of Products under Development for Nasal Polyposis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Nasal Polyposis - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017

Nasal Polyposis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Nasal Polyposis - Pipeline by OptiNose US Inc, H2 2017

Nasal Polyposis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Nasal Polyposis - Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Nasal Polyposis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products ...

List of Figures

Number of Products under Development for Nasal Polyposis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports